New Findings in Pharmacogenomics of Neuropsychiatric Disorders
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 23 November 2024 | Viewed by 76
Special Issue Editors
Interests: pharmacogenomics; genome informatics; bioinformatics of pharmacogenomics; high-throughput DNA sequencing
Special Issues, Collections and Topics in MDPI journals
Interests: pharmacogenomics; pharmacogenetics; personalized medicine; precision medicine; microarray analysis; genomics
Special Issue Information
Dear Colleagues,
Mental and psychiatric disorders, as defined by the World Health Organization (WHO), rank among the most significant global disease burdens. They are continuing to increase, for various reasons, including the inadequate response of patients to the drug treatments currently available on the market. Different patients may exhibit varying responses to the same drug due to genomic variations in their DNA. Pharmacogenomics (PGx) plays a pivotal role in the identification of the genetic markers responsible for these individual differences. Many drugs used in the treatment of psychiatric disorders display an average correlation between clinical responses and plasma/serum concentrations. Recent meta-analyses of randomized controlled trials demonstrated that major-depressive patients who received PGx-guided treatment achieved 71% greater efficacy and symptom remission compared to those receiving standard prescriptions. Other studies have explored potential links between the genotype-predicted activity scores of key pharmacogenes related to neuropsychiatric conditions and the improvement of symptoms and side effects, as reported by pediatric and adolescent patients undergoing treatment with relevant medications. This Special Issue aims to bring together novel research findings that contribute to the field's understanding of the pharmacogenomics of neuropsychiatric disorders. By fostering discussions on genetic markers, treatment efficacy, and individualized approaches, this Special Issue aims to accelerate the translation of pharmacogenomic knowledge into clinical practice, ultimately improving the precision and effectiveness of drug treatments for individuals with neuropsychiatric disorders. This Special Issue also endeavors to spotlight the transformative role of cutting-edge genomic technologies in uncovering pharmacovariants relevant to neuropsychiatric disorders. These technologies, which include, but are not limited to, high-throughput sequencing, CRISPR-based technologies, and advanced bioinformatics tools, could pave the way to a more comprehensive exploration of the genetic landscape that influences drug responses.
Dr. Alireza Tafazoli
Dr. Mandana Hasanzad
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacogenomics
- genome informatics
- advanced DNA-sequencing technologies
- bioinformatics of pharmacogenomics
- diagnostic approaches in the pharmacogenomics of neuropsychiatric disorders
